The Executive Committee both manages and represents ERS by directing and conducting the general activities of the Society on behalf of the General Assembly. The Executive Committee provides an annual report on all activities to the General Assembly.
None
None
None
None
| Company | Nature of Support | Amount of funds received* |
|---|---|---|
| ACI Clinical | Member of Endpoint review panel for bioALS trial | B |
None
No. I declare that I have not been full or part time employee of, paid consultant or advisor to /received a grant from the tobacco industry at any time after 1.1.2000, for any project or programme.
| A | B | C | D |
|---|---|---|---|
| less than € 1'000 | € 1001 - € 5'000 | € 5'001 - € 20'000 | more than € 20'000 |
| Company | Area | Product | Amount of funds received* |
|---|---|---|---|
| Bayer | consultancy | n.a. | B |
None
None
None
| Company | Nature of Support | Amount of funds received* |
|---|---|---|
| BI | unrestricted research grant | D |
| BI | speaker fee | B |
None
No. I declare that I have not been full or part time employee of, paid consultant or advisor to /received a grant from the tobacco industry at any time after 1.1.2000, for any project or programme.
| A | B | C | D |
|---|---|---|---|
| less than € 1'000 | € 1001 - € 5'000 | € 5'001 - € 20'000 | more than € 20'000 |
| Company | Area | Product | Amount of funds received* |
|---|---|---|---|
| Acceleron | Pulmonary Hypertension | Sotatercept | C |
| Merck | Pulmonary Hypertension | Riociguat | C |
| Johnson & Johnson | Pulmonary Hypertension | Macitentan, selexipag | C |
| Bayer | Pulmonary Hypertension | Riociguat | B |
| Ferrer | Pulmonary Hypertension | Treprostinil | B |
| GSK | Asthma | Mepolizumab | B |
| AstraZeneca | Asthma | Benralizumab | B |
| Sanofi | Asthma | Dupilumab | B |
| Novartis | Asthma | Omalizumab | C |
None
None
None
| Company | Nature of Support | Amount of funds received* |
|---|---|---|
| Johnson & Johnson | Translational research grant to the research laboratory | D |
| Bayer | Translational research grant to the research laboratory | C |
None
No. I declare that I have not been full or part time employee of, paid consultant or advisor to /received a grant from the tobacco industry at any time after 1.1.2000, for any project or programme.
| A | B | C | D |
|---|---|---|---|
| less than € 1'000 | € 1001 - € 5'000 | € 5'001 - € 20'000 | more than € 20'000 |
None
None
None
None
None
None
No. I declare that I have not been full or part time employee of, paid consultant or advisor to /received a grant from the tobacco industry at any time after 1.1.2000, for any project or programme.
| A | B | C | D |
|---|---|---|---|
| less than € 1'000 | € 1001 - € 5'000 | € 5'001 - € 20'000 | more than € 20'000 |
None
| Company | Purpose of Payment | Amount of funds received* |
|---|---|---|
| Grifols | advisory board | B |
| CSL Behring | advisory board, lectures | B |
| MSD | advisory board, lectures | B |
| BMS | advisory board, lectures | B |
| Pfizer | advisory board, lectures | B |
| Amgen | advisory board, lectures | B |
| Takeda | advisory board, lectures | B |
| Lekam | advisory board, lectures | B |
| Astra Zeneca | advisory board, lectures | B |
| Roche | lectures | A |
| Novartis | advisory board, lectures | B |
| Boehringer-Ingelheim | lectures | B |
| Company | Purpose and Nature of Benefit | Amount of funds received* |
|---|---|---|
| Astra Zeneca | conference | A |
| MSD | conference | A |
| Amgen | conference | A |
| Pfizer | conference | A |
None
| Company | Nature of Support | Amount of funds received* |
|---|---|---|
| Pfizer | investigator initiated grant | C |
| Astra Zeneca | investigator initiated grant | D |
| CSL Behring | investigator initiated grant | C |
None
No. I declare that I have not been full or part time employee of, paid consultant or advisor to /received a grant from the tobacco industry at any time after 1.1.2000, for any project or programme.
| A | B | C | D |
|---|---|---|---|
| less than € 1'000 | € 1001 - € 5'000 | € 5'001 - € 20'000 | more than € 20'000 |
None
None
None
None
None
None
No. I declare that I have not been full or part time employee of, paid consultant or advisor to /received a grant from the tobacco industry at any time after 1.1.2000, for any project or programme.
| A | B | C | D |
|---|---|---|---|
| less than € 1'000 | € 1001 - € 5'000 | € 5'001 - € 20'000 | more than € 20'000 |
| Company | Area | Product | Amount of funds received* |
|---|---|---|---|
| Novartis | Respiratory | Devices | A |
| GSK | Respiratory | Devices | B |
| TEVA | Respiratory | Devices | B |
| Company | Purpose of Payment | Amount of funds received* |
|---|---|---|
| GSK | Study Design | A |
| Aerogen | Study Design | A |
None
None
| Company | Nature of Support | Amount of funds received* |
|---|---|---|
| GSK | Grant | D |
| Therevance | Grant | D |
None
No. I declare that I have not been full or part time employee of, paid consultant or advisor to /received a grant from the tobacco industry at any time after 1.1.2000, for any project or programme.
| A | B | C | D |
|---|---|---|---|
| less than € 1'000 | € 1001 - € 5'000 | € 5'001 - € 20'000 | more than € 20'000 |
| Company | Area | Product | Amount of funds received* |
|---|---|---|---|
| Novartis, Chiesi, 4DPharma | Airways Disease | Not product specific | D |
| Sanofi/Regeneron, TEVA | Airways Disease | Not product specific | D |
| GSK, Genentech/Roche | Airways Disease | Not product specific | D |
| BI, Mologic, Gossamer, AZ/MedImmune | Airways Disease | Not product Specific | D |
| Shionogi, CSL Behring | Airways Disease | Not product specific | C |
None
None
None
None
None
No. I declare that I have not been full or part time employee of, paid consultant or advisor to /received a grant from the tobacco industry at any time after 1.1.2000, for any project or programme.
| A | B | C | D |
|---|---|---|---|
| less than € 1'000 | € 1001 - € 5'000 | € 5'001 - € 20'000 | more than € 20'000 |
| Company | Area | Product | Amount of funds received* |
|---|---|---|---|
| Astra zeneca | Advisory Board | future plans | A |
| GSK | Advisory Board | future plans | A |
| Novartis | Advisory Board | plans | A |
| Sandoz | Invited speaker | presentation | A |
| Chiesi | Invited speaker&Ad.Board | presentation | A |
| DEVA | Invited speaker&Ad.Board | presentation | A |
| Abdi İbrahim | Invited speaker&Ad.Board | presentation | A |
None
None
None
| Company | Nature of Support | Amount of funds received* |
|---|---|---|
| MSD | Clinical Research | B |
| Sanofi | Clinical Research | B |
None
No. I declare that I have not been full or part time employee of, paid consultant or advisor to /received a grant from the tobacco industry at any time after 1.1.2000, for any project or programme.
| A | B | C | D |
|---|---|---|---|
| less than € 1'000 | € 1001 - € 5'000 | € 5'001 - € 20'000 | more than € 20'000 |
None
None
None
None
None
None
No. I declare that I have not been full or part time employee of, paid consultant or advisor to /received a grant from the tobacco industry at any time after 1.1.2000, for any project or programme.
| A | B | C | D |
|---|---|---|---|
| less than € 1'000 | € 1001 - € 5'000 | € 5'001 - € 20'000 | more than € 20'000 |
None
| Company | Purpose of Payment | Amount of funds received* |
|---|---|---|
| AstraZeneca | Lectures | A |
| Chiesi | Lectures | B |
| GSK | Lectures | B |
| Sanofi Genzyme | Lectures | B |
None
None
| Company | Nature of Support | Amount of funds received* |
|---|---|---|
| Air Liquide Foundation | Research on post-Covid lung involvement | D |
None
No. I declare that I have not been full or part time employee of, paid consultant or advisor to /received a grant from the tobacco industry at any time after 1.1.2000, for any project or programme.
| A | B | C | D |
|---|---|---|---|
| less than € 1'000 | € 1001 - € 5'000 | € 5'001 - € 20'000 | more than € 20'000 |
None
None
None
None
None
None
No. I declare that I have not been full or part time employee of, paid consultant or advisor to /received a grant from the tobacco industry at any time after 1.1.2000, for any project or programme.
| A | B | C | D |
|---|---|---|---|
| less than € 1'000 | € 1001 - € 5'000 | € 5'001 - € 20'000 | more than € 20'000 |
All ERS Assembly Heads are also members of the Executive Committee.
